Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06916806 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

A Phase 1 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
72
Enrollment target
20
Study locations

NCT06916806: Recruiting Phase 1 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus, sponsored by AstraZeneca.

NCT06916806 is a Phase 1 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 72 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06916806, a Phase 1 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
72 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM or RA Study details include: • The study duration will be a minimum of 180 days in addition to the screening period. Additional follow-up visits may be required up to 12 months from study start. * Depending on the study part they are assigned to, participants will be administered AZD5492 once (Part 1) or twice (Part 2). * Study visits will occur at: Screening, Days 1-4, 8, 15, 22, 30, 60, 90, 120, 150, and 180 in Part 1, Screening, Days 1-4, 8-11, 15, 22, 29, 43, 60, 90, 120, 150, and 180 in Part 2.

Primary Outcome

Number and percentage of participants with AEs, AESIs, and SAEs

Conditions Studied

Rheumatoid Arthritis Systemic Lupus Erythematosus Idiopathic Inflammatory Myopathies

Interventions

  • DRUG AZD5492

Study Locations (20)

Other

  • Research Site - Beijing
  • Research Site - Shanghai
  • Research Site - Wuhan
  • Research Site - Bordeaux
  • Research Site - Montpellier
  • Research Site - Nancy
  • Research Site - Paris
  • Research Site - Strasbourg
  • Research Site - Toulouse
  • Research Site - Cologne
  • Research Site - Erlangen
  • Research Site - Magdeburg
  • Research Site - Bunkyō City

Alabama

  • Research Site - Anniston
  • Research Site - Birmingham

California

  • Research Site - La Jolla
  • Research Site - Sacramento

Iowa

  • Research Site - Iowa City

Ontario

  • Research Site - Hamilton

Quebec

  • Research Site - Sherbrooke

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2025-05-01
Est. Completion 2027-06-22
Phase Phase 1
AstraZeneca

1,285 total trials

What NCT06916806 shows while recruiting

NCT06916806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which AZD5492 is the first listed.

NCT06916806 names 20 study sites across 6 states, led by Other, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT06916806 about?

NCT06916806 is a clinical study titled "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.". The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM or RA Study details include: • The study duration will be a minimum of 180 days in addition to the screening period. Additional follow-up visit...

What is the current status of trial NCT06916806?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2025-05-01. Estimated completion is 2027-06-22.

What conditions does trial NCT06916806 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies.

What interventions are being tested in trial NCT06916806?

The interventions under investigation include: AZD5492 (DRUG).

Who is sponsoring clinical trial NCT06916806?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06916806 being conducted?

This trial has 20 study locations across Alabama, California, Iowa, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06916806's enrollment target sits among peer trials

72 132nd of 197 higher than 65 of 197 other Rheumatoid Arthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02359253 · 72 participants · NA

    Robot Aided Rehabilitation - Intervention

  • NCT02962661 · 72 participants · Phase 1

    Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

  • NCT03113643 · 72 participants · Phase 1

    SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  • NCT03187535 · 72 participants · NA

    Effect of TEAS on PONV After Spinal Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06916806

Source: ClinicalTrials.gov NCT06916806, the US trial registry maintained by the National Library of Medicine. NCT06916806 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.